Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leronlimab in CCR5+ advanced solid tumors
NCT04504942Phase 2Completed
- Sponsor
- CytoDyn Inc.
- Start
- May 2020
- Primary completion
- Nov 2021
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of leronlimab in solid tumor, sponsored by CytoDyn Inc. Primary endpoints: Adverse Events at 16 months, Serious Adverse Events at 16 months and 1 more. Started May 2020; status: completed.
02
Drugs
leronlimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04504942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04504942.